190 related articles for article (PubMed ID: 36753744)
21. YAP1 maintains active chromatin state in head and neck squamous cell carcinomas that promotes tumorigenesis through cooperation with BRD4.
Chen N; Golczer G; Ghose S; Lin B; Langenbucher A; Webb J; Bhanot H; Abt NB; Lin D; Varvares M; Sattler M; Egloff AM; Joh R; Uppaluri R; Emerick KS; Lawrence MS; Saladi SV
Cell Rep; 2022 Jun; 39(11):110970. PubMed ID: 35705032
[TBL] [Abstract][Full Text] [Related]
22. Mutant HRAS as novel target for MEK and mTOR inhibitors.
Kiessling MK; Curioni-Fontecedro A; Samaras P; Atrott K; Cosin-Roger J; Lang S; Scharl M; Rogler G
Oncotarget; 2015 Dec; 6(39):42183-96. PubMed ID: 26544513
[TBL] [Abstract][Full Text] [Related]
23. Zinc-Dependent Regulation of ZEB1 and YAP1 Coactivation Promotes Epithelial-Mesenchymal Transition Plasticity and Metastasis in Pancreatic Cancer.
Liu M; Zhang Y; Yang J; Zhan H; Zhou Z; Jiang Y; Shi X; Fan X; Zhang J; Luo W; Fung KA; Xu C; Bronze MS; Houchen CW; Li M
Gastroenterology; 2021 Apr; 160(5):1771-1783.e1. PubMed ID: 33421513
[TBL] [Abstract][Full Text] [Related]
24. Quantitative Proteomics Reveals Fundamental Regulatory Differences in Oncogenic HRAS and Isocitrate Dehydrogenase (IDH1) Driven Astrocytoma.
Doll S; Urisman A; Oses-Prieto JA; Arnott D; Burlingame AL
Mol Cell Proteomics; 2017 Jan; 16(1):39-56. PubMed ID: 27834733
[TBL] [Abstract][Full Text] [Related]
25. Yes-associated protein 1 (YAP1) promotes human gallbladder tumor growth via activation of the AXL/MAPK pathway.
Li M; Lu J; Zhang F; Li H; Zhang B; Wu X; Tan Z; Zhang L; Gao G; Mu J; Shu Y; Bao R; Ding Q; Wu W; Dong P; Gu J; Liu Y
Cancer Lett; 2014 Dec; 355(2):201-9. PubMed ID: 25218593
[TBL] [Abstract][Full Text] [Related]
26. Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas.
Mudianto T; Campbell KM; Webb J; Zolkind P; Skidmore ZL; Riley R; Barnell EK; Ozgenc I; Giri T; Dunn GP; Adkins DR; Griffith M; Egloff AM; Griffith OL; Uppaluri R
Clin Cancer Res; 2021 Apr; 27(8):2326-2339. PubMed ID: 33547198
[TBL] [Abstract][Full Text] [Related]
27. miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis.
Kang W; Huang T; Zhou Y; Zhang J; Lung RWM; Tong JHM; Chan AWH; Zhang B; Wong CC; Wu F; Dong Y; Wang S; Yang W; Pan Y; Chak WP; Cheung AHK; Pang JCS; Yu J; Cheng ASL; To KF
Cell Death Dis; 2018 Jan; 9(2):92. PubMed ID: 29367737
[TBL] [Abstract][Full Text] [Related]
28. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
[TBL] [Abstract][Full Text] [Related]
29. AXL activates YAP through the EGFR-LATS1/2 axis and confers resistance to EGFR-targeted drugs in head and neck squamous cell carcinoma.
Okamoto K; Ando T; Izumi H; Kobayashi SS; Shintani T; Gutkind JS; Yanamoto S; Miyauchi M; Kajiya M
Oncogene; 2023 Sep; 42(39):2869-2877. PubMed ID: 37591955
[TBL] [Abstract][Full Text] [Related]
30. Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.
Skinner HD; Giri U; Yang LP; Kumar M; Liu Y; Story MD; Pickering CR; Byers LA; Williams MD; Wang J; Shen L; Yoo SY; Fan YH; Molkentine DP; Beadle BM; Meyn RE; Myers JN; Heymach JV
Clin Cancer Res; 2017 Jun; 23(11):2713-2722. PubMed ID: 28476872
[No Abstract] [Full Text] [Related]
31. Tyrosine kinase SRC-induced YAP1-KLF5 module regulates cancer stemness and metastasis in triple-negative breast cancer.
Zou H; Luo J; Guo Y; Tong T; Liu Y; Chen Y; Xiao Y; Ye L; Zhu C; Deng L; Wang B; Pan Y; Li P
Cell Mol Life Sci; 2023 Jan; 80(2):41. PubMed ID: 36633714
[TBL] [Abstract][Full Text] [Related]
32. YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling.
Coggins GE; Farrel A; Rathi KS; Hayes CM; Scolaro L; Rokita JL; Maris JM
Cancer Res; 2019 Dec; 79(24):6204-6214. PubMed ID: 31672841
[TBL] [Abstract][Full Text] [Related]
33. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib.
Giles KM; Kalinowski FC; Candy PA; Epis MR; Zhang PM; Redfern AD; Stuart LM; Goodall GJ; Leedman PJ
Mol Cancer Ther; 2013 Nov; 12(11):2541-58. PubMed ID: 24026012
[TBL] [Abstract][Full Text] [Related]
34. MiR-103a-3p promotes tumour glycolysis in colorectal cancer via hippo/YAP1/HIF1A axis.
Sun Z; Zhang Q; Yuan W; Li X; Chen C; Guo Y; Shao B; Dang Q; Zhou Q; Wang Q; Wang G; Liu J; Kan Q
J Exp Clin Cancer Res; 2020 Nov; 39(1):250. PubMed ID: 33218358
[TBL] [Abstract][Full Text] [Related]
35. Axl mediates tumor invasion and chemosensitivity through PI3K/Akt signaling pathway and is transcriptionally regulated by slug in breast carcinoma.
Li Y; Jia L; Ren D; Liu C; Gong Y; Wang N; Zhang X; Zhao Y
IUBMB Life; 2014 Jul; 66(7):507-18. PubMed ID: 24984960
[TBL] [Abstract][Full Text] [Related]
36. Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1.
Yan H; Yu CC; Fine SA; Youssof AL; Yang YR; Yan J; Karg DC; Cheung EC; Friedman RA; Ying H; Chen EI; Luo J; Miao Y; Qiu W; Su GH
Oncogene; 2021 Dec; 40(50):6759-6771. PubMed ID: 34663879
[TBL] [Abstract][Full Text] [Related]
37. Loss of p53-DREAM-mediated repression of cell cycle genes as a driver of lymph node metastasis in head and neck cancer.
Brennan K; Espín-Pérez A; Chang S; Bedi N; Saumyaa S; Shin JH; Plevritis SK; Gevaert O; Sunwoo JB; Gentles AJ
Genome Med; 2023 Nov; 15(1):98. PubMed ID: 37978395
[TBL] [Abstract][Full Text] [Related]
38. A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring
Lee HW; Sa JK; Gualberto A; Scholz C; Sung HH; Jeong BC; Choi HY; Kwon GY; Park SH
Clin Cancer Res; 2020 Oct; 26(19):5113-5119. PubMed ID: 32636318
[TBL] [Abstract][Full Text] [Related]
39. Tyrosine phosphorylation of RAS by ABL allosterically enhances effector binding.
Ting PY; Johnson CW; Fang C; Cao X; Graeber TG; Mattos C; Colicelli J
FASEB J; 2015 Sep; 29(9):3750-61. PubMed ID: 25999467
[TBL] [Abstract][Full Text] [Related]
40. [Doublecortin-like kinase 1 activates Hippo pathway to promote migration, invasion and proliferation of pancreatic cancer cells].
Yan R; Liang ZW; Liu HS; Ge Y; An GY
Zhonghua Zhong Liu Za Zhi; 2023 Jul; 45(7):594-604. PubMed ID: 37462016
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]